Insulin Articles
B-MS metformin potential in AIDS patients?
27 July 2000
Eli Lilly's 2nd-qtr EPS increases 17%
25 July 2000
Czech Rep's Spofa insulin forecasts
21 July 2000
Spofa of Czech Republic posts loss
17 July 2000
Stock Commentary Europe
22 June 2000
Islet cell transplants a step nearer for diabetics?
15 June 2000
Aventis' basal insulin cleared in Europe
15 June 2000
ADA meeting - SB to study Avandia in long-term trial
14 June 2000
Novo Nordisk gains FDA OK for NovoLog
8 June 2000
MoliChem completes Ph I study of CF drug
1 June 2000
W-L in $50M diabetes deal with Metabolex
19 May 2000
Flamel 1st qtr results
15 May 2000
Stock Commentary Tokyo
11 May 2000
"Robust" 1st qtr for Novo Nordisk
5 May 2000
Lilly granted new indications for Humalog
4 May 2000
Novo Nordisk taking Aventis to court
28 April 2000
Eli Lilly Ranbaxy launches HumaPen
27 April 2000
Earnings rise 18% at Eli Lilly
17 April 2000
Big sales boost for reformulated drugs
13 March 2000
Flamel raises $12.8M
10 March 2000
Ligand presents data on new antidiabetic drug
25 February 2000
Generex' insulin spray in trials
24 February 2000
Novo Nordisk sales increase 17%
21 February 2000
Dainippon licenses AJ-9677 to Takeda
17 February 2000
Novo Nordisk settles Lilly patent dispute
2 February 2000
Spofa signs CIS insulin deal
24 January 2000
Polish pharma sale brought forward
24 January 2000
Recent developments in drug delivery - by Mark Greener
19 January 2000
Amylin's exendin-4 shows promise in Ph II
11 January 2000
Novartis seeks US, European Starlix OK
23 December 1999
Stock Commentary Tokyo
16 December 1999
AstraZeneca unveils promising portfolio with 57 NCEs
14 December 1999
Stock Commentary Tokyo
9 December 1999
Novo Nordisk pretax profits increase 11%
12 November 1999
DeveloGen AG: using developmental biology in regenerative medicine
11 November 1999
Amylin to file for Symlin OK in mid-2000
10 November 1999
Eli Lilly suffers from poor Prozac sales
22 October 1999
Protein Delivery begins Phase II with oral insulin
21 October 1999
Novo Nordisk to build new facility
21 October 1999
Novartis' nateglinide "corrects metabolic defect"
14 October 1999
Biotech Holdings announces major collaboration with US firm
11 October 1999
Flamel starts trials of long-acting insulin
11 October 1999
Insulin glargine reduces hypoglycemia risks
11 October 1999
Takeda licenses novel diabetes drug
11 October 1999
Transdermal insulin shows promise
30 September 1999
DIAB II study in Brazil completed
23 September 1999
EU OKs NovoRapid and Norditropin SimpleXx
16 September 1999
Xenical "reduces CV disease risk;" bosentan trial data
7 September 1999
Xenical "reduces CV disease risk"
3 September 1999
Biotech Holdings seeks Brazilian OK for DIAB II
2 September 1999
EC invites comments on Pfizer/HMR deal
2 September 1999
EC inquiry into Pfizer/HMR insulin pact
24 August 1999
Novo Nordisk prepares to list enzymes sector
23 August 1999
Kinetek awarded patent for diabetes compound
12 August 1999
Novo Nordisk sales rise 13%, signs pact with Japan's Takeda
12 August 1999
Novo Nordisk's recombinant Velosulin OKed in USA
27 July 1999
Takeda moves domestic capacity abroad
20 July 1999
Stock Commentary Tokyo
15 July 1999
Pfizer/HMR building vast insulin plant
6 July 1999
Pfizer-backed inhaled insulin starts Phase III
1 July 1999
Exendin-4 enters Phase II
1 July 1999
Novo Nordisk's Prandin plus Rezulin, insulin
24 June 1999
Inhaled insulin delivery shows promise
23 June 1999
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
